28th Apr 2021 19:17
Okyo Pharma Ltd - London-headquartered biotechnology company - Announces positive results of OK-201, a non-opioid analgesic drug candidate, following its delivery in a mouse neuropathic corneal pain model, demonstrating its potential to treat acute and chronic ocular pain.
OK-201 also demonstrated a reduced corneal pain response similar to that of gabapentin, a commonly used oral drug for neuropathic pain. These observations demonstrated preclinical 'proof-of-concept' for the topical administration of OK-201 as a potential non-opioid analgesic for ocular pain. Current treatments for corneal pain are limited to short term NSAIDs, steroids, and oral gabapentin and opioids in severe cases.
Current stock price: 7.65 pence, up 5.5%
Year-to-date change: up 2.0%
By Dayo Laniyan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
OKYO.L